Article Text
PDFViewpoint
Commentary
Ethics of paediatric end-of-life decision making and consent for publication
Statistics from Altmetric.com
Footnotes
-
Competing interests None.
-
Provenance and peer review Commissioned; internally peer reviewed.
Request Permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information:
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions
Linked Articles
- Editorial
- Viewpoint
- The concise argument
Read the full text or download the PDF:
Other content recommended for you
- Spinal muscular atrophy – type I
- Nusinersen for SMA: expanded access programme
- Outcome of goal - directed non-invasive ventilation and mechanical insufflation / exsufflation in spinal muscular atrophy type I
- British Thoracic Society guideline for respiratory management of children with neuromuscular weakness
- Healthcare utilisation in children with SMA type 1 treated with nusinersen: a single centre retrospective review
- Protocol for a phase II, monocentre, double - blind, placebo - controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2–4 (SPACE trial)
- Spinal muscular atrophy: untangling the knot?
- Association of motor milestones, SMN2 copy and outcome in spinal muscular atrophy types 0–4
- Financial, opportunity and psychosocial costs of spinal muscular atrophy: an exploratory qualitative analysis of Australian carer perspectives
- Congenital heart disease is a feature of severe infantile spinal muscular atrophy